(Reuters) -Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and Human Services ...

Novavax Inc. shares plunged as much as 26% after US Health and Human Services Secretary Robert F. Kennedy Jr. raised doubts ...

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay.

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

Shares of Novavax, Inc. (NVAX) plunged over 19.5% on Thursday after Health and Human Services Secretary Robert F. Kennedy Jr.

Novavax (NasdaqGS:NVAX) experienced a noteworthy 13% increase in its share price last week, coinciding with significant changes in its leadership. The retirement of James Young as Chair of the Board ...

Just last week, the US Food and Drug Administration delayed a decision on full approval of Novavax’s Covid-19 vaccine even though it was on track to be cleared, leaving many public health ...

President Trump's trade policies are sending many stocks that were performing well in the wrong direction and exacerbating ...

Health secretary Robert F. Kennedy Jr. this week is sowing doubt about the safety and efficacy of some vaccines — beyond the ...

The delay dovetails with moves by Republican lawmakers in at least 7 states to ban or limit mRNA vaccines. HealthDay News — The US Food and Drug Administration (FDA) has delayed the full ...